Insider Transactions in Q2 2021 at Epizyme, Inc. (EPZM)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2021
|
David M Mott Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,858
+1.71%
|
$22,864
$8.31 P/Share
|
|
Jun 30
2021
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,805
+7.86%
|
$14,440
$8.31 P/Share
|
|
Jun 11
2021
|
Victoria Richon Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,060
+37.19%
|
-
|
|
Jun 11
2021
|
Carl Goldfischer Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,060
+38.16%
|
-
|
|
Jun 11
2021
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,060
+29.41%
|
-
|
|
Jun 11
2021
|
David M Mott Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,060
+4.75%
|
-
|
|
Jun 11
2021
|
Andrew R Allen Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,060
+28.16%
|
-
|
|
Jun 11
2021
|
Michael F Giordano Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,060
+50.0%
|
-
|
|
Jun 11
2021
|
Grant C. Bogle President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,060
+50.0%
|
-
|
|
Jun 11
2021
|
Kenneth Bate Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,060
+50.0%
|
-
|
|
Apr 05
2021
|
Jeffery Kutok Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,029
-3.62%
|
$16,232
$8.8 P/Share
|